Literature DB >> 6130953

Kinetics and metabolism of (+)-, (-)- and (+/-)-bufuralol.

R J Francis, P B East, J Larman.   

Abstract

Single oral doses of (+)-, (-)- and (+/-)-bufuralol were administered to a healthy volunteer to compare the disposition and metabolism of the individual isomers and the racemate. Plasma levels and area under plasma curve (AUC) of the active isomer, (-)-bufuralol, were higher than those of the (+)-isomer; plasma clearance was correspondingly lower. Intermediate values were found for the racemate. The elimination half-life of (-)-bufuralol was shorter than that of (+)-bufuralol, but similar to the racemate. Both isomers were cleared almost entirely by metabolism. The main metabolic pathway for (-)-bufuralol was aromatic hydroxylation, whereas the principal route for (+)-bufuralol was conjugation. Phenol metabolites in the systemic circulation were present mainly as conjugates. Both isomers also underwent aliphatic hydroxylation. This pathway was more favoured by the (+)-isomer, although plasma levels and AUC of the principal product, 2'-hydroxy-bufuralol, were almost identical for the two forms. Major differences in metabolic fate thus had relatively little effect on the disposition of pharmacologically active metabolites.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6130953     DOI: 10.1007/bf00637501

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Decrease of peripheral resistance after acute intravenous application of a new beta-receptor blocking agents, bufuralol HCl.

Authors:  D Magometschnigg; J Bonelli; G Hitzenberger; G Kaik; A Korn
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-02

3.  Intrinsic sympathomimetic activity of beta-adrenoceptor blocking drugs at cardiac and vascular beta-adrenoceptors.

Authors:  T C Hamilton; V Chapman
Journal:  Life Sci       Date:  1978-08-28       Impact factor: 5.037

4.  Bufuralol, a new beta-adrenoceptor blocking agent in a series of benzofuran-2-ethanolamines. Part 2: pharmacology.

Authors:  T C Hamilton; M W Parkes
Journal:  Arzneimittelforschung       Date:  1977-07

5.  Pharmacokinetics of dextro-, laevo- and racemic propranolol in man.

Authors:  C F George; T Fenyvesi; M E Conolly; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

6.  Presystemic and systemic glucuronidation of propranolol.

Authors:  T Walle; T C Fagan; E C Conradi; U K Walle; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

7.  The genetic control of bufuralol metabolism in man.

Authors:  P Dayer; L Balant; F Courvoisier; A Kupfer; A Kubli; A Gorgia; J Fabre
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

8.  Simultaneous determination of d- and l-propranolol in human plasma by high-performance liquid chromatography.

Authors:  J Hermansson; C von Bahr
Journal:  J Chromatogr       Date:  1980-11-14

9.  No stereoselective first-pass hepatic extraction of propranolol.

Authors:  G P Jackman; A J McLean; G L Jennings; A Bobik
Journal:  Clin Pharmacol Ther       Date:  1981-09       Impact factor: 6.875

10.  Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.

Authors:  K Tawara; K Kawashima; H Ishikawa; K Yamamoto; K Saito; A Ebihara; S Yoshida
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

View more
  7 in total

1.  Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol.

Authors:  P Dayer; T Leemann; A Marmy; J Rosenthaler
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s.

Authors:  Bo Lindmark; Anna Lundahl; Kajsa P Kanebratt; Tommy B Andersson; Emre M Isin
Journal:  Br J Pharmacol       Date:  2018-04-19       Impact factor: 8.739

3.  Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation.

Authors:  C Zekorn; G Achtert; H J Hausleiter; C H Moon; M Eichelbaum
Journal:  Klin Wochenschr       Date:  1985-11-15

4.  Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.

Authors:  P Dayer; L Balant; A Kupfer; R Striberni; T Leemann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance.

Authors:  H R Ochs; P Hajdú; D J Greenblatt
Journal:  Klin Wochenschr       Date:  1986-07-15

6.  Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells.

Authors:  Xiaocui Ma; Yuyou Duan; Benjamin Tschudy-Seney; Garrett Roll; Iman Saramipoor Behbahan; Tijess P Ahuja; Vladimir Tolstikov; Charles Wang; Jeannine McGee; Shiva Khoobyari; Jan A Nolta; Holger Willenbring; Mark A Zern
Journal:  Stem Cells Transl Med       Date:  2013-05-16       Impact factor: 6.940

7.  Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.

Authors:  P Dayer; T Leemann; A Küpfer; T Kronbach; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.